Thomas Powles, MD, PhD, FCRP, tell us about the novel antibody-drug conjugate enfortumab vedotin

Umang Swami, MD, explains that new real-world data help to answer critical questions about the role of enfortumab vedotin in advanced urothelial carcinoma.

The FDA approved subcutaneous nivolumab across all adult solid tumor indications for nivolumab.

Arlene O. Siefker-Radtke, MD, shares 2024’s top news in bladder cancer care, including the NIAGRA trial and data on perioperative treatment and biomarkers.

After the withdrawal of sacituzumab govitecan in metastatic bladder cancer, Ulka Vaishampayan, MBBS, discusses next steps, ongoing trials, and treatment options.

The accelerated approval of sacituzumab govitecan for advanced or metastatic bladder cancer was withdrawn after a trial failed to show a survival benefit.

Adding SBRT to pembro increased disease control and appeared to improve OS in some advanced urothelial carcinomas, data from the real-world ARON-2 study show.

Sacituzumab govitecan had significant activity in cisplatin-ineligible patients with advanced bladder cancer who progressed after checkpoint inhibitor use.

Data at ESMO 2024 show perioperative durvalumab plus chemo boosts survival in muscle-invasive bladder cancer, prompting a call for an immediate practice change.

Practice-changing data in breast, cervical, and anal cancers, along with news on novel therapies and long-term survival results, are anticipated at ESMO 2024.

Amid recent FDA approvals for bladder cancer, access to these new options has been a challenge for some patients. Scot Niglio, MD, discusses key obstacles.

Some bladder cancer specialists say that the FDA’s guidance on BCG-unresponsive status hinders care. “It’s making it pretty damn confusing,” said one expert.

Enfortumab vedotin plus pembrolizumab has upended bladder cancer care. But do you know what specific toxicities to watch for, especially early in treatment?